ArticleNeurology(R) neuroimmunology & neuroinflammation2025
The Inner Nuclear Layer in Pediatric Multiple Sclerosis.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Inner Nuclear Layer in Pediatric Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesPediatric onset multiple sclerosis (POMS) leads to optic nerve and retinal damage from optic neuritis (ON) and potential subclinical disease activity. Neuroaxonal retinal damage manifests in peripapillary retinal nerve fiber layer (pRNFL) and macular ganglion cell and inner plexiform layer (GCIP) thinning. Inner nuclear layer (INL) thickness has been suggested to increase with inflammatory activity or after acute ON, and decrease from chronic neurodegeneration. Macular microcysts in the INL have been described in patients with adult MS. The objective of this study was to investigate the INL in a large cohort of POMS as a potential biomarker for evaluation of disease course and therapeutic success.
methodsFor this cross-sectional case-control study, we prospectively recruited 153 patients with POMS and 92 controls, including asymptomatic healthy volunteers and children admitted to the hospital with nonretinal disorders. Optical coherence tomography was performed including intraretinal segmentation. Visual function was determined as best corrected visual acuity (BCVA).
resultsEyes of children with POMS with prior ON had increased INL thickness (44.31 µm) compared with control eyes (42.96 µm, DISCUSSION: The INL in POMS shows changes similar to what has been reported in adults, with macular microcysts being much rarer. A lack of cross-sectional association between INL thickness and disease severity may represent the early disease stage with neuroinflammation instead of neurodegeneration being in focus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.